Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 13/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.35 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
| ▸ | DDR1 | Q08345 | 3/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25315913 | 0.88 | ESR2 (0.39) | OPRK1OPRD1 | |
| SCHEMBL30506821 | 0.88 | ESR2 (0.39) | OPRK1OPRD1 | |
| SCHEMBL25316799 | 0.86 | BACE1 (0.35) | OPRL1IP6K1PTGDR2DDR1OPRM1 | |
| SCHEMBL30506793 | 0.78 | DDR1 (0.41) | DDR1 | |
| SCHEMBL31436447 | 0.78 | DDR1 (0.41) | OPRL1OPRK1IP6K1OPRD1DDR1 | |
| SCHEMBL25317620 | 0.78 | DDR1 (0.41) | DDR1 | |
| SCHEMBL30507038 | 0.75 | TACR1 (0.35) | OPRK1OPRD1 | |
| SCHEMBL25317240 | 0.75 | TACR1 (0.35) | OPRK1OPRD1 | |
| SCHEMBL30804497 | 0.75 | OPRL1 (0.42) | OPRL1OPRK1OPRM1EGLN1 | |
| SCHEMBL25315612 | 0.74 | PRMT5 (0.42) | OPRK1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11976067-B2 | APOL1 inhibitors and methods of use | MAZE THERAPEUTICS, INC. (US) | 2024-05-07 | — | — | US | disclosed |
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
| WO-2023141432-A2 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, LDLR | OPRL1 122/4885OPRK1 1495/4885IP6K1 3004/4885 |
| US-11976067-B2 | APOL1 inhibitors and methods of use | APOL1, APOB, LDLR | OPRL1 122/4885OPRK1 1495/4885IP6K1 3004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.